Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kirsten A. Weigel-Van Aken"'
Autor:
Li Zhong, Nicholas Muzyczka, Sergei Zolotukhin, Lakshmanan Govindasamy, Giridhararao Jayandharan, Kirsten A. Weigel-Van Aken, Roland W. Herzog, Cathryn Mah, Baozheng Li, Arun Srivastava, Mavis Agbandje-McKenna, Jacqueline A. Hobbs
Publikováno v:
Virology. 381(2):194-202
We have documented that epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling negatively affects intracellular trafficking and transduction efficiency of recombinant adeno-associated virus 2 (AAV2) vectors. Specifically, inhib
Autor:
Daniela Bischof, Njeri Maina, Kirsten A. Weigel-Van Aken, Li Zhong, Zongchao Han, Zhongbo Hu, Arun Srivastava, Xiaomiao Li, Mervin C. Yoder, William B. Slayton
Publikováno v:
Human Gene Therapy. 19:376-383
Although conventional recombinant single-stranded adeno-associated virus serotype 2 (ssAAV2) vectors have been shown to efficiently transduce numerous cells and tissues such as brain and muscle, their ability to transduce primary hematopoietic stem c
Autor:
Li Zhong, Kirsten A. Weigel-Van Aken, Zhongbo Hu, Arun Srivastava, William B. Slayton, Xiaomiao Li, Mervin C. Yoder, Nitin Chouthai, Zongchao Han, Daniela Bischof, Njeri Maina
Publikováno v:
Human Gene Therapy. 19:267-278
We previously reported that among single-stranded adeno-associated virus (ssAAV) vectors, serotypes 1 through 5, ssAAV1 is the most efficient in transducing murine hematopoietic stem cells (HSCs), but viral second-strand DNA synthesis remains a rate-
Autor:
Kirsten A. Weigel-Van Aken
Publikováno v:
Human gene therapy. 20(12)
Parvovirus B19 has potential as a gene therapy vector because of its restricted tropism for human erythroid progenitor cells in the bone marrow. B19 binds to the cell surface through P antigen and we identified activated beta(1) integrins as corecept
Autor:
Sergei Zolotukhin, Li Zhong, Kenneth H. Warrington, Lakshmanan Govindasamy, Nicholas Muzyczka, Arun Srivastava, Irene Zolotukhin, Roland W. Herzog, Mario Cooper, Kirsten A. Weigel-Van Aken, Baozheng Li, Mavis Agbandje-McKenna, Cathryn Mah, Jacqueline A. Hobbs
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 105(22)
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits. Large vector doses also trigger an immune response as a significant fr
Autor:
Daniela Bischof, Sergei Zolotukhin, Li Zhong, Njeri Maina, Mervin C. Yoder, William B. Slayton, Weihong Zhao, Angela Rivers, George Aslanidi, Kirsten A. Weigel-Van Aken, Zongchao Han, Xiaomiao Li, Arun Srivastava
Publikováno v:
Human gene therapy. 19(4)
Therapeutic levels of expression of the beta-globin gene have been difficult to achieve with conventional retroviral vectors without the inclusion of DNase I-hypersensitive site (HS2, HS3, and HS4) enhancer elements. We generated recombinant adeno-as
Publikováno v:
PLoS ONE
PLoS ONE, Vol 5, Iss 11, p e13820 (2010)
PLoS ONE, Vol 5, Iss 11, p e13820 (2010)
Background Lactic acid, a natural by-product of glycolysis, is produced at excess levels in response to impaired mitochondrial function, high-energy demand, and low oxygen availability. The enzyme involved in the production of β-amyloid peptide (Aβ
Autor:
Njeri Maina, Li Zhong, Xiaomiao Li, Weihong Zhao, Zongchao Han, Daniela Bischof, George Aslanidi, Sergei Zolotukhin, Kirsten A. Weigel-Van Aken, Angela E. Rivers, William B. Slayton, Mervin C. Yoder, Arun Srivastava
Publikováno v:
Human Gene Therapy; Apr2008, Vol. 19 Issue 4, p365-375, 11p
Autor:
Njeri Maina, Zongchao Han, Xiaomiao Li, Zhongbo Hu, Li Zhong, Daniela Bischof, Kirsten A. Weigel-Van Aken, William B. Slayton, Mervin C. Yoder, Arun Srivastava
Publikováno v:
Human Gene Therapy; Apr2008, Vol. 19 Issue 4, p376-383, 8p
Autor:
Zongchao Han, Li Zhong, Njeri Maina, Zhongbo Hu, Xiaomiao Li, Nitin S. Chouthai, Daniela Bischof, Kirsten A. Weigel-Van Aken, William B. Slayton, Mervin C. Yoder, Arun Srivastava
Publikováno v:
Human Gene Therapy; Mar2008, Vol. 19 Issue 3, p267-278, 12p